‘Viead’ cruises both in prescription and import

While ‘Viread(generic name: tenofovir), the Gilead’s hepatitis B therapy, outnumbered BMS’s ‘Baraclude’ and became the top in the ETC drug market, it continued a smooth flow as recording a significant growth in the import amount.

Based on the ‘2015 Pharmaceutical Manufacturing Performance’ recently published by the Ministry of Food and Drug Safety, Viread was imported for USD 671.38 million(KR...